Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1.
| Image |  |
|---|---|
| Description | scientific article published on 19 October 2016 |
| Author/s |
author: Hisato Kawakami |
| Publication date | December 1, 2016 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |